Survey Reveals Gaps in Fungal Diagnostics and Antifungal Access in Latin America

A multinational survey spanning Latin America and the Caribbean has spotlighted a persistent bottleneck in the region’s fight against invasive fungal disease: where diagnosis is delayed or incomplete, treatment can arrive too late—or not at all. Reported in Nature Communications, the study evaluated how well health systems can detect fungal infections and how readily clinicians can access key antifungal drugs across participating countries.

Researchers from the ESCMID EFISG network collected data from settings that vary widely in laboratory capacity, clinical staffing, and procurement infrastructure. The findings indicate that many patients face practical barriers before confirmatory testing is possible, including limited access to advanced diagnostics such as culture facilities, species-level identification methods, and timely susceptibility testing. As fungal pathogens often require pathogen-specific therapy, these gaps can translate into empiric treatment that is either suboptimal or prolonged.

The survey also examined the drug-access landscape for commonly used antifungals. Even when drugs are included in formularies, availability in real-world clinical practice can be inconsistent due to supply constraints, funding variability, and regional differences in distribution. For clinicians managing rapidly progressive disease, such discontinuities are clinically significant, particularly when therapeutic windows narrow.

A technical takeaway emerges from the gap between recommended diagnostic pathways and what can be executed at scale. The study underscores that laboratory turnaround time matters: slow confirmation can increase reliance on clinical or radiological suspicion, which may not accurately distinguish fungal species. That uncertainty, in turn, affects selection of therapy and can influence outcomes.

By linking diagnostics and drug access in the same regional snapshot, the work reframes fungal management as an integrated system problem rather than two separate challenges. It highlights that improving antifungal stewardship requires not only prescribing guidance, but also reliable laboratory workflows and dependable medication supply chains.

Although invasive fungal disease is influenced by patient-level factors such as immunosuppression, the survey’s emphasis on system-level readiness points to interventions that public health and hospital networks can implement. Streamlined diagnostic referral, standardized testing algorithms, and procurement strategies aligned with clinical urgency could reduce avoidable delays.

Overall, the study provides a viral-science-news style warning signal: in a region where fungal threats do not wait, both rapid identification and consistent antifungal availability must improve together. The survey’s cross-national design offers a foundation for benchmarking and targeted reforms aimed at turning diagnostic capability into timely, effective treatment.